The Israel Institute for Biological Research and NRx Pharmaceuticals have signed an MOU to complete clinical trials and commercialize “BriLife”
NRx Pharmaceuticals, an international company traded on Nasdaq, will complete the clinical trials needed to increase the statistical sample and to prepare the necessary regulatory files in order to continue the clinical trials and conduct its third phase. The company will conduct clinical trials on tens of thousands of volunteers in the countries with which it has signed cooperation agreements. IIBR will accompany the process and will continue to share knowledge and provide scientific assistance to complete the clinical trials.